D-(Boc)Val-L-Leu | 74201-99-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: D-(Boc)Val-L-Leu
• 英文别名: N^α-(t-butoxycarbonyl)-D-valylleucine；D-(N-tert-butoxycarbonylvalyl)-L-leucine；(2S)-4-methyl-2-[[(2R)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoyl]amino]pentanoic acid
• CAS: 74201-99-3
• 化学式: C₁₆H₃₀N₂O₅
• 分子量: 330.425
• InChiKey: PUUABEGDHGDROR-NWDGAFQWSA-N

物化性质

• 沸点：
  516.3±35.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  D-(Boc)Val-L-Leu 在 N-甲基吗啉 、 sodium hydroxide 、 N-羟基丁二酰亚胺 、 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 25.0h， 生成 {(S)-5-(2-Benzyloxycarbonylamino-ethylcarbamoyl)-5-[(S)-2-((R)-2-tert-butoxycarbonylamino-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-pentyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  An Approach Towards More Selective Anticancer Agents

  摘要：

  一种有前景的方法是利用与人类恶性肿瘤相关的蛋白酶增强表达来更好地靶向抗癌药物治疗。特别是，已经发现纤溶酶原激活剂的活性显著提高，导致丝氨酸蛋白酶纤溶酶的活性增加。双功能烷基化剂，如N-(2-氯乙基)-N-亚硝基脲，显示出广泛的抗癌活性，但也表现出相当大的全身毒性。我们在这里描述了一种新型N-亚硝基脲类前药的合成，这些前药设计为通过肿瘤相关的蛋白酶激活，以提供增强的抗肿瘤活性和减少的全身毒性。代表纤溶酶底物的三肽通过酰胺键连接到N’-(2-氨基乙基)-N-(2-氯乙基)-N-亚硝基脲及相应的N’-甲基衍生物。我们描述了这些新三肽结合物的合成和纤溶酶触发的分解。表达高纤溶酶原激活剂活性的癌细胞在纤溶酶原存在的情况下对新前药高度敏感，但在缺乏的情况下则不然。

  DOI：

  10.1055/s-1996-4368
• 作为产物：
  描述：

  Boc-D-缬氨酸 在 palladium on activated charcoal TEA 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 D-(Boc)Val-L-Leu
  参考文献：
  名称：

  环状五肽内皮素A受体拮抗剂的构效关系。

  摘要：

  天然产物内皮素A（ETA）受体拮抗剂的类似物环（-D-Trp1-D-Glu2-Ala3-D-Val4-Leu5-）（1）和环（-D-Trp1-D-Glu2-Ala3-D -alloIle4-Leu5-）（2）的制备和测试对[125I]内皮素（ET-1）与蛋白质ETA受体结合的抑制活性。天然产物的DDLDL手性序列似乎对于抑制活性至关重要，因为D-Trp或D-Glu（或两者）在1中转化为相应的L-异构体消除了该特性。在天然产物的每个位置上的系统修饰阐明了结构-活性关系，并导致了高效和选择性的ETA受体拮抗剂。D-Trp1和Leu5多数被其他氨基酸替代导致抑制活性的显着降低。相反，用D-Asp2替代D-Glu2增强了活性。关于Ala3的位置，所有具有亚氨基酸的类似物，无论是环状的还是无环的，都比氨基酸类似物具有更高的亲和力。另外，大多数在其侧链中具有各种官能团的氨基酸替代物并未显着改变ETA结合亲和力。D-Val4

  DOI：

  10.1021/jm00021a021

文献信息

• Structure-Activity Relationships of Cyclic Pentapeptide Endothelin A Receptor Antagonists
  作者：Takehiro Fukami、Toshio Nagase、Kagari Fujita、Takashi Hayama、Kenji Niiyama、Toshiaki Mase、Shigeru Nakajima、Takahiro Fukuroda、Toshihiko Saeki

  DOI：10.1021/jm00021a021

  日期：1995.10

  D-heteroarylglycine was preferable at this position. Among synthesized cyclic pentapeptides, compound 36 (BQ-518) was the most potent ETA receptor antagonist, with a pA2 of 8.1 against ET-1-induced vasoconstriction in isolated porcine coronary arteries. This compound also showed the greatest selectivity between ETA and ETB receptors (IC50 for human ETA = 1.2 nM, IC50 for human ETB = 55 microM). In contrast, compound

  天然产物内皮素A（ETA）受体拮抗剂的类似物环（-D-Trp1-D-Glu2-Ala3-D-Val4-Leu5-）（1）和环（-D-Trp1-D-Glu2-Ala3-D -alloIle4-Leu5-）（2）的制备和测试对[125I]内皮素（ET-1）与蛋白质ETA受体结合的抑制活性。天然产物的DDLDL手性序列似乎对于抑制活性至关重要，因为D-Trp或D-Glu（或两者）在1中转化为相应的L-异构体消除了该特性。在天然产物的每个位置上的系统修饰阐明了结构-活性关系，并导致了高效和选择性的ETA受体拮抗剂。D-Trp1和Leu5多数被其他氨基酸替代导致抑制活性的显着降低。相反，用D-Asp2替代D-Glu2增强了活性。关于Ala3的位置，所有具有亚氨基酸的类似物，无论是环状的还是无环的，都比氨基酸类似物具有更高的亲和力。另外，大多数在其侧链中具有各种官能团的氨基酸替代物并未显着改变ETA结合亲和力。D-Val4
• Peptide derivatives of primaquine as potential antimalarial agents
  作者：Abraham Philip、John A. Kepler、Bernadette H. Johnson、F. Ivy Carroll

  DOI：10.1021/jm00399a032

  日期：1988.4

  Three peptide derivatives of primaquine were synthesized. The compounds were tested for radical curative antimalarial activity against Plasmodium cynomolgi in rhesus monkeys and blood schizonticidal antimalarial activity against Plasmodium berghei in mice. All three peptide derivatives showed activity against P. cynomolgi greater than that expected for the primaquine content of each prodrug. The toxicity

  合成了伯氨喹的三种肽衍生物。测试了化合物对恒河猴的食蟹猴疟原虫的根治性抗疟活性以及小鼠对柏氏疟原虫的血裂线虫的抗疟活性。所有三种肽衍生物均显示出对食蟹猴的抗性大于对每种前药的伯氨喹含量所预期的活性。在小鼠中，一种肽衍生物的毒性小于伯氨喹。
• Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard
  作者：Prasun K. Chakravarty、Philip L. Carl、Michael J. Weber、John A. Katzenellenbogen

  DOI：10.1021/jm00359a003

  日期：1983.5

  Many tumors contain elevated levels of plasminogen activator and thus produce elevated levels of the protease plasmin in the milieu of the tumor. We have hypothesized, therefore, that it should be possible to prepare peptidyl prodrug derivatives of anticancer drugs that would be locally activated by tumor-associated plasmin. As an initial test of this hypothesis, we synthesized the peptidyl prodrugs of the anticancer drugs (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin, AT-125) and N,N-bis(2-chloroethyl)-p-phenylenediamine (phenylenediamine mustard) by mixed anhydride coupling of the parent drug with the protected tripeptide, Boc-D-Val-Leu-Lys(Boc)-OH, followed by deprotection with trifluoroacetic acid. The prodrugs showed an increased selective in vitro cytotoxicity for Rous sarcoma virus transformed chicken embryo fibroblasts (which produce elevated levels of plasminogen activator) compared to nontransformed fibroblasts (which produce low levels of plasminogen activator). In the presence of the plasmin inhibitor, p-nitrophenyl p'-guanidinobenzoate at 2 micrograms/mL, the selectivity of the phenylenediamine mustard prodrug was reduced, but there was no effect on the cytotoxicity of the free drug. Furthermore, the prodrug analogue D-valylleucyl-D-lysylphenylenediamine mustard (in which L-Lys has been replaced by D-Lys) was inactive. Finally, the prodrug derivative of acivicin did not display selective toxicity for transformed cells when the cells were cultured in plasminogen-free medium. These results suggest that plasmin hydrolysis is necessary for the activation of the prodrugs. The prodrugs were tested in vivo for antitumor activity. The prodrug of acivicin, like acivicin itself, was inactive against the B16 melanoma, a murine tumor that produces high levels of plasminogen activator. This prodrug was active against the M5076 carcinoma, a tumor that displays only moderate levels of plasminogen activator; however, despite the fact that the prodrug was 2- to 3-fold less toxic on a molar basis than acivicin, there was no evidence of an increased therapeutic index. The prodrug of phenylenediamine mustard was also slightly less toxic than the parent drug, but again there was no evidence for an improved therapeutic index against the B16 tumor.
• Novel peptide derivatives of bleomycin A5: Synthesis, antitumor activity and interaction with DNA
  作者：Zhi-Dong Xu、Min Wang、Su-Long Xiao、Ming Yang

  DOI：10.1016/j.bmcl.2005.06.021

  日期：2005.9

  A series of novel amino acid and peptide derivatives of bleomycin (BLM) A(5) were synthesized. All the compounds possessed significant antitumor activities in vitro against HL-60, BGC-823, PC-3MIE8, and MDA-MB-435 cell lines. Their antitumor activities against. MDA-MB-435 were 10-fold higher than BLM A(5). The DNA cleavage studies indicated that the hydrophobic amino acid or peptide derivatives of BLM A(5) could induce higher cleavage ratio of double to single strand DNA than BLM A(5). From the DNA binding studies, we found that the derivatives containing either D-conformation amino acid or basic amino acid could facilitate DNA binding of BLM. (c) 2005 Elsevier Ltd. All rights reserved.
• PHILIP, ABRAHAM;KEPLER, JOHN A.;JOHNSON, BERNADETTE H.;CARROLL, F. IVY, J. MED. CHEM., 31,(1988) N 4, 870-874
  作者：PHILIP, ABRAHAM、KEPLER, JOHN A.、JOHNSON, BERNADETTE H.、CARROLL, F. IVY

  DOI：——

  日期：——